 |
| Spotlight Correspondence |
| ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL) |
|
| B Selle1, C Bär1, S Hecker1, U Schmidt-Rohr1, S Viehmann2, K-M Debatin3 and D Reinhardt4 |
|
1Department of Pediatric Oncology and Hematology, University of Heidelberg, Heidelberg, Germany
2Department of Pediatric Oncology and Hematology, University of Giessen, Giessen, Germany
3Department of Pediatric Oncology and Hematology, University of Ulm, Ulm, Germany
4Department of Pediatric Oncology and Hematology, University of Münster, Münster, Germany
|
Correspondence to: B Selle, Department of Pediatric Oncology and Hematology, University of Heidelberg, Im Neuenheimer Feld 150, D-69120 Heidelberg, Germany; Fax: 0049 6221 565526 |
|
| Abstract |
| Leukemia (2002) 16, 1393-1395. doi:10.1038/sj.leu.2402520 |
|
|
|
|
| Received 4 December 2001; accepted 29 January 2002 |
|
| July 2002, Volume 16, Number 7, Pages 1393-1395 |
| Table of contents Previous Abstract Next Full text PDF |
|
